A growing transatlantic dispute over UK drug pricing has escalated after Trump's ambassador summoned the head of NHS drug pricing authority Nice for a dressing down. The pharmaceutical industry, including US giants like Eli Lilly and British firms AstraZeneca and GSK, is pressuring Prime Minister Starmer to increase payments for innovative medicines, warning that investment will flow elsewhere without higher prices.

Under a deal with Trump last year, Britain promised to raise NHS spending on innovative drugs by 25% and increase cost-effectiveness thresholds from £20,000-£30,000 to £25,000-£35,000 per quality-adjusted life year. However, pharmaceutical companies have not resumed UK investments despite these concessions. Industry leaders argue that without further price increases, Britain will lose research and development to the US and China.

The dispute reflects a fundamental divide: while Nice's Jonathan Benger argues that factors beyond price influence investment decisions, pharmaceutical executives insist Britain must pay more to remain competitive. With NHS medicine spending at 9% of healthcare costs—down from 11% a decade ago and below European levels—the government faces pressure to find ways to increase pharmaceutical investment while maintaining cost controls.